3 ms·
A bit late, Cuba developed one in 2011, available for $1: https://en.wikipedia.org/wiki/CimaVax-EGF https://en.wikipedia.org/wiki/CimaVax-EGF
by RedAuburn 2y ago
A bit late, Cuba developed one in 2011, available for $1: https://en.wikipedia.org/wiki/CimaVax-EGF https://en.wikipedia.org/wiki/CimaVax-EGF
- d_tr 2y agoIs this a joke? You are comparing two very different things.
- adamredwoods 2y agoBenefits seemed very situational, especially for EGFR expression, but the future does seem to be personalized medicine, and this could be another piece to that puzzle. https://aacrjournals.org/clincancerres/article/22/15/3782/79235/A-Phase-III-Clinical-Trial-of-the-Epidermal-Growth https://aacrjournals.org/clincancerres/article/22/15/3782/79... >> Survival benefit was significant (HR, 0.77; P = 0.036) in the per-protocol setting (patients receiving at least four vaccine doses): MST was 12.43 months for the vaccine arm versus 9.43 months for the control arm. MST was higher (14.66 months) for vaccinated patients with high EGF concentration at baseline.